Last reviewed · How we verify

NCT03428074

A Observational Study to Compare Effectiveness and Safety of the Surgeries in Patients With Esophageal Cancer

Completed Last updated 21 May 2018
What this trial tests

trial testing Surgeries in Esophageal Cancer in 1,862 participants. Completed in 30 March 2018.

Timeline
1 December 2017
Primary endpoint
30 March 2018
30 March 2018

Quick facts

Lead sponsorChinese PLA General Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,862
Start date1 December 2017
Primary completion30 March 2018
Estimated completion30 March 2018
Sites9 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Eligibility, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study was designed to compare effectiveness and safety of the surgeries of Ivor-Lewis and Mckeown in patients with esophageal cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effectiveness and safety of minimally invasive Ivor Lewis and McKeown oesophagectomy in Chinese patients with stage IA-IIIB oesophageal squamous cell cancer: a multicentre, non-interventional and observational study.
    Zhang T, Hou X, Li Y, Fu X, et al · · 2020 · cited 22× · PMID 32285107 · DOI 10.1093/icvts/ivaa038

Verify or expand the search:

Other trials of Surgeries

Trials testing the same drug.

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03428074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing